FELIX

"Keep the Cat Free"
20/05/13

Remote-controlled insulin production

A new use for therapeutic nanoparticles in diabetes treatment
Sharing
4ceb4db26f1f3ff8370a5128df9beb06.gif
... but only in mice, so far

Researchers in New York have engineered a way to non-invasively trigger gene activation in live animals using nanoparticles and radio waves, a method that may, in the future, be used to remotely control genes in humans for medical purposes.

Current methods of activating cells are unwieldy at best: direct stimulation using electrodes is invasive, potentially damaging and non-specific, whilst control of individual light-activated channels using different wavelengths of precisely-timed light pulses requires internally implanted light pipes. But, by abusing the properties of iron oxide nanoparticles (FeNPs) and temperature-sensitive ion channels, the researchers found a way to finely control certain genes non-invasively.

Jeffery Friedman and colleagues of The Rockefeller University targeted FeNPs to a modified, temperature-sensitive cation channel, TRPV1 (otherwise known as the capsaicin receptor) by coating the nanoparticles with antibodies specific to a modified tag on the channel. Exposure to low- and mid-range radio wave frequencies heated up the targeted nanoparticles but not the surrounding tissue, thereby activating the channel upon reaching its activation temperature. The resulting calcium ion influx activated a specially modified gene that controlled expression of insulin. This lead to a corresponding drop in blood glucose levels after 30 minutes.

The team also experimented with nanoparticles that could be made intracellularly using modified ferritin, a naturally occurring iron-storage protein.  They saw that insulin secretion still occurred, albeit more weakly.

Radio wave gene activation has the advantage of being both non-damaging to tissue and non-invasive whilst heating surrounding cells to a minimal degree. Currently however the technique can only be used in basic animal research, as the delivery of nanoparticles into a living organism requires the deliberate growth of tumours, making it inappropriate for use in human clinical research.

Friedman hopes though that as research progresses use of nanoparticles in a therapeutic setting will be able to treat diseases involving protein deficiencies, such as hexosaminidase A replacement in Tay-Sachs disease.

DOI: 10.1126/science.1216753

Comments (0 comments)

Post a comment
Comment anonymously or log in

Anonymous comments are moderated before appearing on the website. Comments posted while logged in appear immediately and are moderated later. Read our commenting policy for more information.

Commenting Policy

Felix is fully supportive of fierce and frank discussions. We will generally allow comments that are on-topic and avoid personal attacks; criticising someone's decision is allowed, criticising their weight, for example, is not.

Comments may be deleted/rejected if they:

  • are off-topic
  • contain ad-hominem attacks
  • are potentially libellous
  • use excessively foul language
  • are obviously spam

Email article

Remote-controlled insulin production
(Seperate multiple address with a comma)